| Hua Yang,Yuxue Wei,Gangli Liu. Gene mutation analysis and immune checkpoint therapy in head and neck squamous cell carcinoma. Oncol Transl Med, 2022, 8: 36-42. |
| Gene mutation analysis and immune checkpoint therapy in head and neck squamous cell carcinoma |
| Received:July 08, 2021 Revised:February 21, 2022 |
| View Full Text View/Add Comment Download reader |
| KeyWord:head and neck squamous cell carcinoma (HNSCC); immune checkpoint inhibitor; gene mutation |
| Author Name | Affiliation | Postcode | | Hua Yang | Department of Stomatology, The People''''s Hospital of Lanling County | 277700 | | Yuxue Wei | Department of Stomatology, The People''''s Hospital of Lanling County | | | Gangli Liu | Department of Stomatology, The People''''s Hospital of Lanling County | 250012 |
|
| Hits: 2637 |
| Download times: 2817 |
| Abstract: |
| Immune checkpoint inhibitors (ICI), represented by blocked programmed cell death-1 (PD-1), is a group
of novel medicines for anti-tumor immunotherapy. It has been approved by the U.S. Food and Drug
Administration (FDA) in recent years for relapsed or metastatic head and neck squamous cell carcinoma
(HNSCC), and brings promising treatment prospects. However, the instability caused by tumor gene
mutations significantly compromises the therapeutic effect of ICI. Therefore, the identification and analysis
of HNSCC gene mutations can further guide and optimize the application of ICIs in HNSCC. In this study,
we preliminarily described the clinical research progress of ICI therapy and the potential immune escape
mechanism in HNSCC. An overview of complete HNSCC gene mutation results was generated from the
bioinformatics study of TCGA database to further explain and analyze the relevant molecular mechanisms,
which may aid in designing future personalized therapeutic strategies for HNSCC patients. |
| Close |
|
|
|